首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: Synthesis and biological evaluation
【24h】

Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: Synthesis and biological evaluation

机译:软骨蛋白聚糖酶的芳基磺酰胺抑制剂作为骨关节炎的潜在治疗剂:合成和生物学评估

获取原文
获取原文并翻译 | 示例
       

摘要

Aggrecanases, in particular aggrecanase-2 (ADAMTS-5), are considered the principal proteases responsible for aggrecan degradation in osteoarthritis. For this reason, considerable effort has been put on the discovery and development of aggrecanase inhibitors able to slow down or halt the progression of osteoarthritis. We report herein the synthesis and biological evaluation of a series of arylsulfonamido-based hydroxamates as aggrecanase inhibitors. Compound 18 was found to have a nanomolar activity for ADAMTS-5, ADAMTS-4 and MMP-13 and high selectivity over MMP-1 and MMP-14. Furthermore, this compound proved to be effective in blocking ex vivo cartilage degradation without having effect on cell cytotoxicity.
机译:Aggrecanases,特别是aggrecanase-2(ADAMTS-5),被认为是导致骨关节炎中聚集蛋白聚糖降解的主要蛋白酶。由于这个原因,人们已经在发现和开发能够减慢或阻止骨关节炎进展的软骨聚集蛋白聚糖酶抑制剂上付出了巨大的努力。我们在此报告了一系列作为聚集蛋白聚糖酶抑制剂的基于芳基磺酰胺基的异羟肟酸酯的合成和生物学评估。发现化合物18对ADAMTS-5,ADAMTS-4和MMP-13具有纳摩尔活性,并且相对于MMP-1和MMP-14具有高选择性。此外,该化合物被证明可有效阻止离体软骨降解,而对细胞的细胞毒性没有影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号